IMVT · Immunovant, Inc.
$30.42
-0.05 (-0.16%)
At close · Oct 12
Return incl. dividend (before tax)
Market Cap
$6.29B
Shares
206.55M
Volume · Oct 12
25.57K
Avg daily vol (3M)
1.24M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$30.47
Open$30.25
Day$30.07–30.64
52W close$17.03–44.96
Avg vol 30d1.5M
Short int17.4M · 8.4% float · 9.6d
Short vol75%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held Feb 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$538.22M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$797.80M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+20.3%
Year over year · more shares
Price change (1Y)
+74.3%
Trailing year
Short interest
8.4%
Latest settlement · 9.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−4%
below
Price vs 50-day avg
−21%
below
RSI (14)
21
oversold
MACD trend
Negative
52-week position
48%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
+7%
trailing
YTD return
+20%
this year
Relative strength
−3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $38 › 200d $32 — 50d above 200d
Institutional flow
Accumulating
5 of 229 funds reported for Sep 30 · net +1.5M sh shares
Insider flow
Distributing
Net -$968.1K over 90 days · 100% sells
Short interest
Rising
8.43% of float · ▲ +0.9% MoM · 9.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
229 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
EPS growth
−1%
Y/Y
Free cash flow
$-407.3M
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−4%
Neutral
Price vs 50-day avg
−21%
Bearish
RSI (14)
21
Neutral
MACD trend
Negative
Bearish
52-week position
48%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $38 › 200d $32 — 50d above 200d
Institutional flow
Accumulating
5 of 229 funds reported for Sep 30 · net +1.5M sh shares
Insider flow
Distributing
Net -$968.1K over 90 days · 100% sells
Short interest
Rising
8.43% of float · ▲ +0.9% MoM · 9.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
229 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $17
Now $30 · 48%
Range high $45
vs 200-day avg -4%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net loss (Non-GAAP) non-GAAP | -139.45M | Three months ended June 30, 2026 | — |
| Non-GAAP G&A expenses non-GAAP | $11.2M | Three months ended June 30, 2026 | — |
| Non-GAAP net loss non-GAAP | $139.4M | Three months ended June 30, 2026 | — |
| Non-GAAP R&D expenses non-GAAP | $135.4M | Three months ended June 30, 2026 | — |
| Shares of common stock issued and outstanding | 206,264,878 | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMVT
this stock
Immunovant, Inc.
|
$6.29B | +19.9% | — | — | 8.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMVT | -9.4% | -18.4% | +6.8% | -9.8% | +19.9% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -10.5% | -20.3% | -3.1% | -11.9% | +5.7% |